0.9 (0.1) 0.9 (0.1) 0.9 (0.1) 20-29 0.6 (0.1) 0.6 (0.1) 0.6 (0.1) 1.9 (0.1) 1.9 (0.1) 1.9 (0.1) 3 0.8 (0.1) 0.7 (0.1) 0.8 (0.1) ≥4
1.0 (0.1) 1.1 (0.1) 1.0 (0.1) Duration of hospitalization, non-psychiatric (Mean days) 6.6 (0.2) 6.9 (0.2) 6.7 (0.2) Duration between index and discharge of last hospitalization, days, non-psychiatric (Mean days) 51.9 (0.5) 53.6 (0.5) 52.4 (0.5) 304, 0.8 (0.1) 1.0 (0.1) 0.9 (0.1) General medical conditions, in the past 12 months (%) Acquired immune deficiency syndrome (ICD-9-CM: 042) 0.1 (0.0) 0.1 (0.0) 0.1 (0.0) Asthma (ICD-9-CM: 493) 3.0 (0.2) 2.8 (0.2) 3.0 (0.2) Back pain 722, 723, 724, 739.3, 739.4, 846, 847.2) 16.1 (0.4) 16.4 (0.4) 16.2 (0.4) Cancer 273.0, 273.3, and V10) 1.2 (0.1) 1.2 (0.1) 1.2 (0.1) Cerebrovascular disease (430) (431) (432) (433) (434) (435) (436) (437) (438) 781.4, 784.3, 997.0) 2.6 (0.1) 2.7 (0.2) 2.6 (0.2) eTable 1 continued. 404.x2, 585, 586, V42.0, V45.1, V56.0, V56.8) 0.5 (0.1) 0.6 (0.1) 0.6 (0.1)
III. Clinical diagnoses & comorbid conditions
Chronic liver disease (ICD-9-CM: 571.2-571.9; 456.0-456.2) 1.1 (0.1) 1.1 (0.1) 1.1 (0.1) Chronic pulmonary disease 492, 494, 495, 496) 2.9 (0.2) 2.6 (0.2) 2.8 (0.2) Congestive heart failure 402.11, 302.91, 425, 428, 429.3) 0.9 (0.1) 1.0 (0.1) 1.0 (0.1) Coronary heart disease 3.0 (0.2) 2.7 (0.2) 2.9 (0.2) Diabetes mellitus (ICD-9-CM: 250) 4.6 (0.2) 4.6 (0.2) 4.6 (0.2) Dyslipidemia (ICD-9-CM: 272) 5.0 (0. 441.2, 441.4, 441.7, 441.9, 447.1, 557, 785.4) 0.6 (0.1) 0.5 (0.1) 0.6 (0.1)
Rheumatological disease 710.1, 710.4, 714.0, 714.1, 714.2, 714.81, 725) 0.5 (0.1) 0.7 (0.1) 0.6 (0.1) 0.0 (0.5) 0.0 (0.3) 0.0 (0.5) Anticholinergic, days of outpatient use, past 12 months (Mean) 1.6 (18.9) 1.6 (18.4) 1.6 (18.8) Anti-diabetic agent, concomitant use (%) 2.1 (0.1) 2.2 (0.1) 2.2 (0.1) Anti-diabetic agent, days of inpatient use, past 12 months (Mean) 0.1 (1.5) 0.1 (1.5) 0.1 (1.5) Anti-diabetic agent, days of outpatient use, past 12 months (Mean) 6.0 (37.9) 6.4 (38.9) 6.1 (38.2) Antithrombotic agent, concomitant use (%) 1.6 (0.1) 1.8 (0.1) 1.7 (0.1) Antithrombotic agent, days of inpatient use, past 12 months (Mean) 0. The lasso regression models that generated these coefficients contained only the 10 predictors for each outcome in eTable 3a. We present these coefficients to provide some information on relative importance in the effects of the predictors in their metrics rather than in terms of MSE. See eTable 1 for distributions of the predictors. The regression coefficients reported are multiplied by 100. As in eTable 3, the outcome variables are individual-level differences in predicted probabilities of treatment success based on the medication-specific model compared to the model estimated in the total sample (i.e., combined across all medications). See the methods section of the paper and the citations in that section for more details. Note that it is conventional not to report standard errors for lasso regression. 
IV. Psychotropic agents

